Clinical trials: Influenza Vaccine
Influenza
A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine
This observer-blind study is designed to evaluate the immune response and safety of pandemic influenza vaccine in the elderly population.
- Trial name
- NCT00866580
- Testing
- GSK's candidate influenza vaccine 1562902A, FluarixTM
- Where
- Brazil
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
A Multinational Phase III Study of CS-8958 (MARVEL)
The primary objective of this study is to confirm the efficacy of CS-8958 administered as a single inhaled low dose or single inhaled high dose by showing non-inferiority to oseltamivir phosphate using the time to alleviation of…
- Trial name
- MARVEL (NCT00803595)
- Testing
- CS-8958, oseltamivir phosphate
- Where
- 4 sites in China, Japan and 2 more
- Volunteers
- 1,002 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Haemophilus Influenzae Type B, Hepatitis B
Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)
To determine if there is an improvement in the immune response to HBsAg (hepatitis B virus) in healthy infants using a modified process in a combination Haemophilus Influenzae, type b/Hepatitis B vaccine and a currently licensed…
- Trial name
- NCT00441012
- Testing
- Comparator: Modified Process Vaccine, Comparator: COMVAX™
- Volunteers
- 546 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Influenza
Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers
The purpose of this study is to evaluate the immunogenicity and safety of the investigational vaccine in the subjects during their participation in the study.
- Trial name
- NCT01987011
- Testing
- MG1109
- Where
- 4 sites in South Korea
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Influenza
A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination
To describe the safety of the inactivated, split-virion influenza vaccine, 2008-2009 formulation. To evaluate the compliance, in terms of immunogenicity, of the inactivated, split-virion influenza vaccine 2008-2009 formulation…
- Trial name
- NCT00743275
- Testing
- Split, Inactivated, Trivalent Influenza vaccine (Fluzone®)
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy or Stable Underlying Chronic Medical Condition
A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age
The objective of this study was to show that quadrivalent live attenuated influenza vaccine (Q/LAIV; MEDI3250) produced antibody levels similar to those produced by the commercial vaccine, FluMist.
- Trial name
- MI-CP185 (NCT00860067)
- Testing
- Q/LAIV (MEDI3250), FluMist/B/Yamagata, FluMist/B/Victoria
- Where
- 18 sites in United States
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Phase II Study of Pandemic Influenza Vaccine
The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is the leading candidate to cause the next influenza pandemic.
- Trial name
- NCT00320346
- Testing
- Pandemic Influenza Vaccine
- Where
- 3 sites in Australia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Seqirus
END STAGE RENAL DISEASE
A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine
The purpose of this explorative trial is to collect preliminary data on efficacy and safety of thymosin alpha 1 given at different doses as an adjuvant to egg-derived H1N1sw monovalent influenza vaccine in hemodialysis patients.
- Trial name
- NCT01031966
- Testing
- MF59 adjuvanted H1N1 influenza monovalent vaccine, Thymosin alpha 1
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Influenza
Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers
This study was designed in two steps with Step 1, a single-center, double-blind, randomized clinical Pilot study and Step 2, a multi-center, single-blind, randomized clinical Pivotal study.
- Trial name
- NCT01389466
- Testing
- Step 1, Step 2
- Where
- 4 sites in South Korea
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Seasonal Influenza
Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010
This study is an annual trial for registration of inactivated split influenza vaccine with strain composition for season 2009/2010.
- Trial name
- NCT00945841
- Testing
- inactivated split influenza vaccine
- Where
- 3 sites in Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza, Human
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older
Study to evaluate the safety and immunogenicity of H7N9 antigen in combination with full or half doses of AS03 adjuvant system in healthy adults.
- Trial name
- NCT04789577
- Testing
- FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3
- Where
- 8 sites in United States
- Volunteers
- 833 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy, Immunogenicity of ASP7374
A Study to Evaluate the Immune Response to the ASP7374 and Its Safety in Healthy Adult Volunteers
This trial is designed as a blinded, randomized and parallel group study to investigate the clinically recommended dosage for ASP7374 based on the comparison of the immunogenicity and safety among two doses of subcutaneous…
- Trial name
- NCT01393951
- Testing
- ASP7374
- Where
- Japan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- UMN Pharma Inc.
Influenza, Orthomyxoviridae Infections
Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine
Following the licensure of sanofi pasteur's 90 µg rgA/Vietnam/1203/2004 pandemic influenza vaccine, efforts to develop a lower antigen dose formulation with improved immunogenicity using adjuvants were initiated.
- Trial name
- NCT00664417
- Testing
- Monovalent subvirion H5N1 influenza vaccine, Physiological saline
- Where
- 6 sites in United States
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza
Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population
As influenza vaccine efficacy is reported to be lower in elderly subjects compared to healthy adults, probably as a result of immunosenescence, there is a desire to devise ways to increase the current vaccines efficacy for this…
- Trial name
- NCT00318149
- Testing
- Fluarix, Fluarix-AS25, Fluarix-AS50
- Where
- Belgium
- Volunteers
- 425 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine
Primary objective: Immunogenicity To demonstrate that the influenza vaccine administered by intradermal route at least as immunogenic as the adjuvanted influenza vaccine administered by intramuscular route at the same dosage in…
- Trial name
- NCT00554333
- Testing
- Flu-ID 15μg, Inactivated adjuvanted Influenza Vaccine
- Where
- 8 sites in Belgium, France
- Volunteers
- 795 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications
This study will evaluate the efficacy, safety, and population pharmacokinetics of a single, oral dose of GP681 compared with placebo in patients aged 12 and older With Influenza at High Risk of Influenza Complications.
- Trial name
- NCT06573008
- Testing
- GP681 40mg, GP681 Simulant
- Where
- China
- Volunteers
- 328 people, healthy volunteers welcome
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Influenza
Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults
This study is designed to characterize the safety and immunogenicity of a' pandemic influenza (H1N1) candidate vaccine GSK2340274A in adults 19 to 40 years who have never received influenza vaccination.
- Trial name
- NCT01059617
- Testing
- GSK Biologicals' FluLaval®, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A
- Where
- 3 sites in United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Avian Influenza
A Safety and Immunogenicity Study of IVACFLU-A/H5N1
The study hypothesis was that two 0.5 mL doses of whole virion monovalent A/H5N1 influenza vaccine (IVACFLU-A/H5N1) adjuvanted with alum would be safe and well tolerated in healthy adults, and that at least one of the two doses…
- Trial name
- NCT02612909
- Testing
- IVACFLU-A/H5N1 vaccine
- Where
- 2 sites in Vietnam
- Volunteers
- 930 people, healthy volunteers welcome
- Sponsor
- Institute of Vaccines and Medical Biologicals, Vietnam
Influenza
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
This study is designed to test the immunogenicity and reactogenicity of the Fluarix™/Influsplit SSW® influenza vaccine containing the influenza strains recommended for the 2010-2011 season.
- Trial name
- NCT01144299
- Testing
- Fluarix™/Influsplit SSW®
- Where
- 6 sites in Germany
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infectious Disease by Haemophilus Influenzae Type b
Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study
This is a multi-center, comparative, two-arm, parallel-group, single-blind, phase III study to assess immunogenicity and safety of 4th LBVH0101 (Haemophilus influenzae type b tetanus toxoid conjugate vaccine) vaccination compared…
- Trial name
- NCT01251133
- Testing
- LBVH0101 (Hib vaccine), Hiberix™ Vaccine
- Where
- South Korea
- Volunteers
- 122 people
- Sponsor
- LG Life Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.